While GLP-1 receptor agonists and SGLT2 inhibitors have demonstrated efficacy in glucose lowering and weight reduction, their effects plateau over time, and they rarely achieve diabetes remission. The gene discussed is GLP1R; the disease is diabetes mellitus.